Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)
Clinical trial NCT05926180 · COMPLETED
Trial details
- NCT number
- NCT05926180
- Sponsor
- Dizal Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-31
- Primary completion
- 2024-05-16
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.